ID Biomedical Gets U.S. Flu Drug Deal  MONTREAL (Reuters) - ID Biomedical Corp. &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=IDB.TO target=/stocks/quickinfo/fullquote"&gt;IDB.TO&lt;/A&gt; &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=IDBE.O target=/stocks/quickinfo/fullquote"&gt;IDBE.O&lt;/A&gt;  signed a 10-year U.S. distribution deal for its Fluviral drug  that could reap sales of \$2.3 billion and help U.S. authorities  fill a flu vaccine shortage, the company said on Monday.